Prasugrel formindskede eksponeringen for hydroxybupropion, en CYP2B6- medieret metabolit af bupropion, hos raske forsøgspersoner med 23%.
In healthy subjects, prasugrel decreased exposure to hydroxybupropion, a CYP2B6-mediated metabolite of bupropion, by 23%.